<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90566">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01709253</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS 07-253</org_study_id>
    <nct_id>NCT01709253</nct_id>
  </id_info>
  <brief_title>Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma</brief_title>
  <official_title>Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>clinical outcomes</measure>
    <time_frame>up to 5years from a initial follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate biochemical failure-free survival (BCFFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>up to 5years from a initial follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate acute toxicities by CTCAE version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>up to 5years from a initial follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluated late toxicities by CTCAE version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 5years from a initial follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>to evaluated overall survival</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>proton beam therapy</intervention_name>
    <description>hypofractionation study using proton beam therapy for prostate adenocarcinoma</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 ECOG performance status: 0-2
        Signed study specific informed consent prior to study entry

        Exclusion Criteria:

        Postoperative residual or recurrent tumor Evidence of distant metastases Previous
        irradiation for the tumor in the same location Adjuvant anti-androgenic hormonal therapy
        High risk group (NCCN guide line)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>kwan ho cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>kwan ho cho, M.D.</last_name>
    <phone>+82 31 920 1720</phone>
    <email>kwancho@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National cancer center, korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do,</state>
        <zip>411-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kwan ho cho, M.D.</last_name>
      <phone>+82 31 920 1720</phone>
      <email>kwancho@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>kang hyun lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byong ho nam, ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>yeon-joo kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 16, 2012</lastchanged_date>
  <firstreceived_date>October 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Kwan Ho Cho</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>hpofractionation study using proton beam therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
